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Abstract
Background: Patients with gynecologic cancer have a high risk of venous thromboembolism (VTE) like patients
with other cancers. However, there is little information on risk factors for VTE during gynecologic surgery and no
uniform preventive strategy. Our objectives were to identify risk factors for perioperative VTE in gynecologic
patients and establish methods for prevention.
Methods: We analyzed 1,232 patients who underwent surgery at the Department of Obstetrics and Gynecology of
St. Marianna University School of Medicine between January 2005 and June 2008. We investigated (1) risk factors
for preoperative VTE, (2) use of an inferior vena cava (IVC) filter, and (3) risk factors for postoperative VTE.
Results: There were 39 confirmed cases of perioperative VTE (3.17%), including 25 patients with preoperative VTE
and 14 with postoperative VTE. Thirty-two patients had cancer and seven patients had benign diseases. Twenty-
two of the 32 cancer patients (68.7%) had preoperative VTE, while postoperative VTE occurred in 10 cancer
patients. Multivariate analysis indicated that ovarian cancer, tumor diameter ≥10 cm, and previous of VTE were
independent risk factors for preoperative VTE. Among ovarian cancer patients, multivariate analysis showed that an
age ≥50 years, the presence of heart disease, clear cell adenocarcinoma, and tumor diameter ≥20 cm were
independent risk factors for preoperative VTE. The factors significantly related to preoperative VTE in patients with
benign disease included previous VTE, age ≥55 years, tumor diameter ≥20 cm, and a history of allergic-
immunologic disease. Thirteen of the 25 patients (52%) with preoperative VTE had an IVC filter inserted
preoperatively. Postoperative screening (interview and D-dimer measurement) revealed VTE in 14/1,232 patients
(1.14%). Multivariate analysis indicated that cancer surgery, a history of allergic-immunologic disease, and blood
transfusion ≥2,000 ml were independent risk factors for postoperative VTE.
Conclusions: Perioperative VTE is often fatal and preventive measures should be taken in the gynecologic field,
especially when patients have the risk factors identified in this study. Since VTE is often present before surgery,
preoperative screening is important and use of an IVC filter should be considered.
Background
In recent years, a rapid increase of venous thromboem-
bolism (VTE) has occurred in Japan with aging of the
population, more complex operations, and new thera-
peutic procedures related to improvements of
catheterization and implantation techniques [1]. A pre-
vious study of patients undergoing abdominal surgery by
Sakon et al. identified four factors, which were (1)
female sex, (2) intrapelvic surgery, (3) an age ≥60 years,
and (4) an operating time ≥3 hours, as risk factors for
postoperative VTE [1]. The incidence of VTE increased
along with the number of risk factors and exceeded 60%
in patients with all four factors. The authors concluded
that VTE is common in Japanese patients after major
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prophylaxis, especially in patients with multiple risk fac-
tors [1]. According to Edition 8 of the American College
of Chest Physicians (ACCP) Guidelines, the incidence of
asymptomatic deep venous thromboembolism (DVT)
based on objective diagnostic screening is 15-40%
among patients undergoing major gynecologic surgery
without preventive measures, which is the same as for
general surgery, major urological operations, and neuro-
surgery [2]. The results of a survey of perioperative pul-
monary thromboembolism (PE) in Japan showed a
prevalence of 4.41 episodes per 10,000 operations. The
number of cases in the gynecology field ranked third
behind orthopedic surgery and gastroenterology [3].
When VTE prophylaxis was not performed, the occur-
rence of fatal PE increased, the cost of treatment
became higher, recurrence was more common, and
major adverse events (such as the chronic thrombotic
syndrome) occurred [2]. Preoperative and perioperative/
postoperative PE accounted for 24.3% and 75.6% of
these cases, respectively. Since almost all PE occurred
postoperatively, especially after laparotomy for malig-
nant tumors, both preoperative/perioperative prevention
and prevention of postoperative VTE are important in
such patients [3]. The above reports suggest that it is
also necessary to strengthen preventive measures for
perioperative VTE in the field of gynecology, and it is
important to identify the risk factors for this condition.
Surgery for gynecologic cancer shows several differ-
ences from general surgery. Patients often require intra-
pelvic procedures, such as lymph node dissection and
excision of peritoneal metastases, and it is likely that
VTE will occur at a high incidence in these cases.
Lymph node dissection is one of the risk factors for
VTE because of possible venous damage [4]. In the
gynecologic cancer field, 50% of patients with postopera-
tive PE have endometrial cancer because 62.5% of such
patients have a body mass index (BMI) ≥25 kg/m
2 and
standard surgery includes lymph node dissection [4].
Dissection of para-aortic lymph nodes is also sometimes
performed, which significantly increases the incidence of
VTE compared to that in patients only receiving dissec-
tion of the intrapelvic nodes [4]. Because lymph node
dissection increases the risk of thrombosis during or
soon after surgery and residual tumor sometimes exists
postoperatively in ovarian cancer patients, it is necessary
to take preventive measures against VTE from the early
postoperative period. It has been reported 45% of VTE
occurs on the day of surgery [5], so it is important to
use methods such as intermittent pneumatic compres-
sion (IPC) during and after surgery to prevent VTE.
According to an analysis of 1,974 patients with gyne-
cologic cancer by Santoso et al., the incidence of DVT
was 4.2% (36/853) and 0.2% (2/1,121) in patients with
gynecological cancer or benign tumors, respectively, and
the risk of DVT was 2.8 times higher in gynecologic
cancer patients [6]. An analysis of 6,218 patients with
gynecologic disease receiving IPC as the only preventive
method showed an incidence of 0.68% (42/6,218) for
postoperative PE, including 0.32% (10/3,518) for benign
disease and 2.21% (32/1,451) for cancer patients [4].
Multivariate analysis of patients with and without IPC
showed significant differences in the risk of PE for can-
cer surgery, BMI ≥25 kg/m
2, and blood transfusion, with
the risk ratios being 2.860, 3.922, and 3.834, respectively.
Therefore, obese women receiving blood transfusion
postoperatively are high-risk patients who require very
strict management. With prophylactic IPC, the risk of
postoperative PE was significantly reduced by about 60%
(risk ratio: 0.396), indicating that at least employing IPC
after gynecologic surgery is important [4]. According to
as u r v e yo f1 , 0 7 3g y n e c o l o g i co n c o l o g i s t sf r o mt h e
Society of Gynecologic Oncology undertaken by Martino
et al., 41% only performed IPC to prevent perioperative
VTE, while 16% only used anticoagulant therapy and
42% used both methods [7]. At present, a preventive
strategy has not been established for postoperative VTE
in cancer patients, including those with gynecologic can-
cer [8]. In Japan, it is assumed that physicians are unli-
kely to perform both IPC and anticoagulant therapy at a
higher level than in the above report. When we investi-
gated this issue previously [4], prevention of postopera-
tive VTE was limited to use of IPC and anticoagulation
was not performed at that time. In the present study,
we investigated risk factors related to postoperative VTE
in patients with gynecologic disease who received both
IPC and anticoagulant therapy. Among cancer patients,
Camps et al. reported that ovarian cancer follows pan-
creatic, gastric, urological, and brain cancer as the dis-
ease with the highest risk of VTE [9]. Since it is
therefore quite possible that VTE will have already
occurred before the start of treatment, it is important to
undertake preoperative screening of ovarian cancer
patients. In the present study, therefore, we also investi-
gated the risk factors related to preoperative VTE in
patients with gynecologic diseases.
Methods
We analyzed 1,232 patients who underwent surgery at
the Department of Obstetrics and Gynecology of St.
Marianna University School of Medicine (Kanagawa,
Japan) between January 2005 and June 2008. Surgery for
obstetric procedures or infertility and cervical conization
were excluded. Patients were evaluated by measurement
of the D-dimer level (Mitsubishi Chemical Iatron,
Tokyo, Japan), as well as by electrocardiography, arterial
blood gas analysis, chest X-ray examination, and echo-
cardiography. Confirmation of the diagnosis of VTE was
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ultrasonography of leg vein pulsation. We performed
the chest helical CT and ultrasonography of leg vein to
the patients with high D-dimer levels before and after
the operation. IPC alone or IPC combined with an
anticoagulant [danaparoid sodium (Schering-Plough,
Osaka, Japan) administered intravenously at 1,250 units/
day for 5 to 7 days starting preoperatively] was
employed to prevent postoperative VTE. As previously
reported [4], the combination of IPC and anticoagula-
tion (danaparoid sodium) was routinely used for cancer
patients. Patients with benign disease and a BMI
≥25 kg/m
2 or those receiving blood transfusion were
also given the combination of IPC and danaparoid
sodium. This combined prophylaxis was performed in
23.1% (284/1,232) of all surgical patients.
Statistical analysis
To investigate factors related to preoperative VTE, uni-
variate analysis was performed to assess the relation
between VTE and 14 variables, including the age (≥50
years old or ≥55 years old), BMI (≥25 kg/m
2 or ≥28 kg/
m
2), presence or absence of complications (hyperten-
sion, abnormal glucose tolerance, allergic-immunologic
disease, heart disease, hyperlipidemia, and VTE), use or
non-use of hormone preparations, benign or malignant
disease, and tumor diameter (≥10 cm or ≥20 cm). Selec-
tion of variables was performed by the stepwise method
or the scoring method. Then the following five variables
were employed for multivariate analysis (Multiple Logis-
tic Regression): age ≥50 years, presence/absence of heart
disease, presence/absence of VTE, ovarian cancer, and
tumor diameter ≥10 cm.
To assess factors related to preoperative VTE in ovar-
ian cancer patients, univariate analysis was performed
with 14 variables, which were the same as those listed
above, except that “clear cell adenocarcinoma” was sub-
stituted for “benign or malignant disease”.V a r i a b l e
selection was performed by the stepwise or scoring
methods, resulting in selection of the following four
variables for multivariate analysis (Multiple Logistic
Regression): age ≥50 years, presence or absence of heart
disease, clear cell adenocarcinoma, and tumor diameter
≥20 cm.
For investigation of factors related to preoperative
VTE in patients with benign diseases, univariate analysis
was performed with 13 variables after deleting “benign
or malignant disease” from the initial 14 variables. To
detect factors related to postoperative VTE, univariate
analysis was done to assess the relation between VTE
and the following 21 variables: age (≥50 years old or
≥55 years old), BMI (≥25 kg/m
2 or ≥28 kg/m
2), presence
or absence of complications (hypertension, abnormal
glucose tolerance, allergic-immunologic disease, heart
disease, hyperlipidemia, and VTE), use or non-use of
hormone preparations, benign or malignant disease,
operating time (≥4h o u r so r≥6 hours), postoperative
blood loss (≥1,000 ml, ≥1,500 ml, or ≥2,000 ml), perio-
perative blood transfusion (≥1,000 ml and ≥2,000 ml),
and tumor diameter (≥10 cm or ≥20 cm). After variable
selection was performed by the stepwise or scoring
methods, the following three variables were used for
multivariate analysis (Multiple Logistic Regression): the
presence or absence of allergic-immunologic disease,
surgery for benign or malignant disease, and periopera-
tive blood transfusion ≥2,000 ml.
All statistical analyses were performed using SAS soft-
ware version 8.2 (SAS Institute, Cary, NC, USA).
Indications for inferior vena cava (IVC) filter insertion
The D-dimer level was measured and computed tomo-
graphy (CT) was performed immediately before surgery
in cancer patients and patients with large benign
tumors. An IVC filter (Gunter Tulip Vena Cava Filter,
Cook Medical) was inserted preoperatively if PE was
detected and there was pulmonary dysfunction due to
microthrombi or if proximal DVT was detected even in
the absence of PE.
Results and Discussion
Characteristics of VTE patients with gynecologic diseases
(Table 1)
We analyzed 1,232 patients who underwent surgery at
the Department of Obstetrics and Gynecology of St.
Marianna University School of Medicine between Janu-
ary 2005 and June 2008. VTE was diagnosed in 39/1,232
patients (3.17%), being preoperative in 25/39 patients
(64.1%) and postoperative in 14 patients (35.9%). Thirty-
two of 39 patients (82.1%) had cancer and seven (17.9%)
had benign disease. Sixteen (64%) of the preoperative
VTE patients already had PE, emphasizing the impor-
tance of screening for VTE and PE before surgery. Post-
operative VTE occurred in 14 out of 39 patients
(35.9%). According to previous reports, the incidence of
postoperative DVT and PE in gynecologic cancer
patients was 7-45% and 1-2.6%, respectively [10-12].
Cancer was present in 32 of the 39 VTE patients
(82.1%) with gynecologic disease and perioperative VTE
was significantly more common in cancer patients, as
reported previously [13]. Among patients undergoing
surgery for cancer, the incidence of VTE was 8.70% (32/
3 6 8 ) .A m o n gt h e3 2c a n c e rp a t i e n t s ,t h em a j o r i t yh a d
preoperative VTE (68.7%; 22/32), while 10 patients had
postoperative VTE. The incidence of VTE in patients
with uterine cervical cancer, endometrial cancer, and
ovarian cancer was 3%, 2.56%, and 18.1% respectively.
The incidence of VTE was significantly higher in
patients with ovarian cancer than in those with other
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benign disease, only 7/864 (0.81%) had VTE, which was
preoperative in three of the seven patients (42.9%) and
postoperative in four patients (57.1%). These results
indicated that perioperative VTE is significantly more
common among gynecological patients with cancer (p <
0.01, Student’s t-test). There were no significant differ-
ences of age and BMI between patients with preopera-
tive or postoperative VTE, but tumor diameter was
significantly larger in patients with a postoperative onset
(p < 0.01, Student’s t-test).
Characteristics of patients with gynecologic disease and
preoperative VTE
Screening for preoperative VTE by interview, D-dimer
testing, and preoperative imaging showed that only six
out of 25 patients (24%) with preoperative VTE had
symptoms such as dyspnea, while most of them had
silent thrombosis. The mean D-dimer value of the
25 patients was 20.3 μg/ml and IVC filters were inserted
preoperatively in 13 of them (52%).
VTE was present preoperatively in 22 out of 368 can-
cer patients (5.98%) and 21 of them (95.5%) had ovarian
cancer or tubal cancer. Thus, in 14.6% (21/144) of the
patients scheduled to undergo surgery for ovarian or
tubal cancer, VTE was present preoperatively (Table 1).
There was DVT only, PE only, or DVT plus PE in
nine, two, and 14 patients, respectively, and 16 of the 25
patients (64%) had PE.
Results of multivariate analysis of preoperative VTE
Since an accurate screening method for perioperative
VTE is not available at present, we investigated risk fac-
tors for preoperative VTE in patients undergoing gyne-
cologic surgery by performing univariate and
multivariate analyses. The initial univariate analysis
identified age (≥50 years old and ≥55 years old), a
history of VTE, ovarian cancer, and tumor diameter
(≥10 cm and ≥20 cm) as being significantly related to
preoperative VTE (Table 2). When multivariate analysis
was performed with the five variables shown in Table 2,
there was a significant association between VTE and
ovarian cancer, tumor diameter ≥10 cm, and a history
of VTE, with the risk ratios being 20.521, 6.442, and
34.596, respectively.
Fotopoulou et al. reported an analysis of 2,743 patients
with ovarian cancer from in three prospective rando-
mized trials of postoperative platinum/paclitaxel-based
chemotherapy performed by the Arbeitsgemeinschaft
Gynaekologische Onkologie Ovarian Cancer Study
Group [14]. They found 76 cases of VTE among
patients who received 6 to 11 cycles of chemotherapy
and it occurred within 2 months postoperatively in 50%
of these patients. Their multivariate analysis showed
that a BMI ≥30 kg/m
2 and old age were independent
risk factors for VTE in ovarian cancer patients. The
overall survival rate was significantly reduced by VTE
and PE was a significant adverse prognostic factor [14].
Table 1 Incidence and type of perioperative VTE in patients with gynecologic disease
Total VTE (n) Preoperative (n) Postoperative (n)
All gynecologic diseases (n = 1,232) 39 25 14
Benign diseases (n = 864) 7 3 4
Malignant diseases (n = 368) 32* 22 10
Uterine cervical cancer (n = 100) 3 0 3
Endometrial cancer (n = 117) 3 1 2
Ovarian cancer/tubal cancer (n = 144) 26* 21 5
Age, years (range) 60.6 (42-88) 58.0 (40-75)
BMI, kg/m
2 (range) 21.7 (16.6-28.5) 22.2 (16.4-27.8)
Tumor diameter, cm (range) 16.9 (6-30)* 10.3 (3-20)*
*: Significant difference by Student’s t-test (p < 0.01).
BMI: body mass index; VTE: venous thromboembolism.
Table 2 Risk factors for preoperative VTE
Univariate analysis
Variable p value
Age ≥50 years <0.01
Age ≥55 years <0.01
History of VTE <0.01
Ovarian cancer <0.01
Tumor diameter ≥10 cm <0.01
Tumor diameter ≥20 cm <0.01
Multivariate analysis
Variable Risk ratio 95% CI p value
Lower Upper
History of VTE 34.596 2.003 597.612 <0.05
Age ≥50 years 2.368 0.657 8.531 0.187
Ovarian cancer 20.521 5.046 83.455 <0.01
Tumor diameter ≥10 cm 6.442 1.280 32.412 <0.05
Heart disease 0.763 0.032 18.2 0.867
CI: confidence interval; VTE: venous thromboembolism.
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patients in the California Cancer Registry, 5.2% of the
patients developed VTE within 2 years of diagnosis and
it has an adverse effect on their prognosis. Certain coa-
gulation-related factors produced by ovarian cancer cells
may increase the risk of VTE and this can be decreased
by 30% after the tumor size is reduced by surgery [15].
Characteristics of preoperative VTE in ovarian
cancer patients
The mean age and mean tumor diameter of the 20 ovar-
ian cancer patients with preoperative VTE (excluding
tubal cancer patients) was 58.2 (43-75) years and 18.7
(10-27) cm, respectively. Two patients (10%) had serous
carcinoma, while the histology was endometrioid in five
patients (25%), mucinous in one patient (5%), and clear
cell in 12 patients (60%). Since we found that 21 out of
22 cancer patients (95.5%) with preoperative VTE had
ovarian or tubal cancer, we performed an analysis of vari-
ables related to the occurrence of preoperative VTE in
ovarian cancer patients. The results of univariate analysis
using 14 variables showed that a diagnosis of clear cell
adenocarcinoma and the tumor diameter (≥10 cm or
≥20 cm) were significantly associated with preoperative
VTE (Table 3). When multivariate analysis was per-
formed using four variables, a significant association with
VTE was observed for a tumor diameter ≥20 cm, clear
cell adenocarcinoma, and age ≥50 years, with risk ratios
being 29.942, 9.052, and 9.953, respectively (Table 3).
In support of our results, it has been reported that
ovarian cancer is associated with the same high risk of
VTE as pancreatic cancer and brain cancer [16]. Tateo
et al. reported that ovarian cancer was associated with
the highest risk of VTE among gynecologic diseases
[17]. A study of 253 ovarian cancer patients revealed
VTE in 42 patients (16.6%) and PE in four of these 42
patients (1.6%). VTE was discovered before the start of
treatment in 3.2% (n = 8), postoperatively in 2.4%
(n = 6), during first-line postoperative chemotherapy in
4.8% (n = 12), and during post-treatment follow-up in
4.8% (n = 12). Multivariate analysis indicated that inde-
pendent risk factors for the occurrence of VTE during
the treatment of ovarian cancer were the presence of
residual tumor, age (risk increasing with each decade),
and BMI (risk increasing with each 5 kg/m
2). Unlike
Tateo et al. [17], we investigated ovarian cancer patients
with confirmed preoperative VTE, but both studies indi-
cate that tumor diameter and age are important factors
related to VTE. However, the role of clear cell carci-
noma may be specific to Japan. Satoh et al. previously
reported that clear cell carcinoma and massive ascites
are risk factors for preoperative DVT in ovarian cancer
patients based on multivariate analysis [18]. Satoh et al.
also reported that extrauterine progression and histology
other than endometrioid adenocarcinoma were risk fac-
tors for preoperative VTE in endometrial cancer patients
[19]. Furthermore, Black et al. found that progressive
ovarian cancer (stages III and IV), ascites, and residual
lesions ≥1 cm independent risk factors for postoperative
VTE in patients with ovarian or tubal cancer [20].
Characteristics of preoperative VTE in patients with
benign diseases
Among 864 patients with benign gynecological diseases,
preoperative VTE was found in only three (0.35%).
These three patients were an 80-year-old woman with
an ovarian tumor measuring 23 cm in diameter and a
history of VTE, a 42-year-old woman with an ovarian
tumor and a history VTE, and an 83-year-old woman
with a BMI of 24 kg/m
2, hyperlipidemia, and hyperten-
sion. The mean age, mean BMI, and mean tumor
diameter of the three patients were 68.3 (42-83) years,
21.1 (15.0-24.7) kg/m
2, and 12 (6-23) cm, respectively.
Univariate analysis of factors related to preoperative
VTE in patients with benign disease using 13 variables
showed that a history of VTE (p <0 . 0 1 ) ,a g e≥55 years
(p < 0.01), tumor diameter ≥20 cm (p <0 . 0 1 ) ,a n d
history of allergic-immunologic disease (p <0 . 0 5 )w e r e
significant risk factors (Table 4). Multivariate analysis
could not be performed because only three patients had
preoperative VTE.
Table 3 Risk factors for preoperative VTE in ovarian
cancer patients
Univariate analysis
Variable p value
Clear cell adenocarcinoma <0.05
Tumor diameter ≥10 cm <0.05
Tumor diameter ≥20 cm <0.01
Multivariate analysis
Variable Risk ratio 95% CI p value
Lower Upper
Tumor diameter ≥20 cm 29.942 5.402 165.946 <0.01
Clear cell adenocarcinoma 9.052 1.929 42.477 <0.01
Age ≥50 years 9.953 1.338 74.047 <0.05
Heart disease 2.442 0.088 67.533 0.598
CI: confidence interval; VTE: venous thromboembolism.
Table 4 Risk factors for preoperative VTE in benign
disease patients (univariate analysis)
Variable p value
History of VTE <0.01
Age ≥55 years <0.01
Tumor diameter ≥20 cm <0.01
Allergic-immunologic disease <0.05
VTE: venous thromboembolism.
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patients with benign diseases (0.46%). These four patients
had ovarian tumors (n = 2), uterine myoma (n = 1), and
intrauterine infection (n = 1). The mean age, mean BMI,
mean tumor diameter, mean operating time, and mean
blood loss were 53.8 years, 23.0 kg/m
2, 12 cm, 144.3 min-
utes, and 1,154 ml, respectively. There were no signifi-
cant differences of these parameters between the 10
cancer patients and four benign disease patients with
postoperative VTE. Santoso et al. reported that the inci-
dence of postoperative DVT was 0.30% (2/720) in
patients with benign disease [6]. Martino et al. reported
that the incidence of PE after major surgery in patients
with benign disease was 0.3% (1/332) [13], while DVT
was detected in 22.2% (2/9) of symptomatic patients with
benign disease. These results indicate that the prevalence
of perioperative VTE among patients with benign gyne-
cological diseases is significantly lower compared with
that among cancer patients. However, even in patients
with benign disease, screening for VTE should be per-
formed preoperatively when patients have risk factors
such as a history of VTE, age ≥55 years, tumor diameter
≥20 cm, or a history of allergic-immunologic disease, and
postoperative screening should be done in patients who
require a large volume of blood transfusion.
Preoperative prevention
In our series, an IVC filter was inserted preoperatively in
13 out of 25 patients (52%) with preoperative VTE
(Table 5). These 13 patients consisted of one with a
benign ovarian tumor, one with endometrial cancer, and
12 with ovarian cancer. Both PE and DVT were present
in nine patients, while one patient had PE alone and
three patients had DVT alone. The filter was placed a
mean of 3.62 (1-15) days preoperatively and was
inserted 1-2 days preoperatively in the majority of cases
(n = 8). The mean D-dimer level of the 13 patients was
20.4 (2.0-75.8) μg/ml. Four patients had the filter
removed after 10 to 15 days.
Case number 5 was 67 years old, nulligravid and nulli-
parous, with menopause at 48 years of age. Her main
complaint was an abdominal mass and ovarian cancer
was suspected. She had a history of hypertension and a
BMI of 25.9 kg/m
2. The D-dimer value on the day of
first examination (day 1) was 0.6 μg/ml. Since the D-
dimer level was a high 9.5 μg/ml (Figure 1A) on the day
of admission (day 20), contrast CT was performed on
the same day, resulting in the diagnosis of PE and DVT
(Figures 1B and 1C). On the days of the initial visit and
admission, there were no symptoms or signs of VTE.
After insertion of an IVC filter via the right subclavian
vein on the day before surgery (day 20), staging laparot-
omy was performed (day 21). After confirming the reso-
lution of VTE by CT, the filter was removed on day 13
after insertion (day 33). The histopathologic diagnosis
was ovarian clear cell adenocarcinoma of International
Federation of Gynecology and Obstetrics (FIGO) stage
IIc. When VTE is detected by preoperative screening,
surgery is often postponed because of anticoagulant
therapy, etc. However, a retrospective study of IVC
filters in 39 patients with gynecologic cancer by Adib
et al. found no filter-related adverse events, indicating
that it is better to insert a filter and not delay the start
of treatment [21]. They reported that it was possible to
perform surgery within 6 days after diagnosis of VTE in
17 of the 39 patients (43%). We inserted an IVC filter
preoperatively in 13 out of 25 patients with preoperative
VTE (52%), and no filter-related adverse events were
observed. The filter was inserted a mean of 3.62 (1-15)
days preoperatively and the majority of filters were
inserted 1-2 days preoperatively (n = 8). Case number
5 with ovarian clear cell carcinoma did not have VTE at
Table 5 Patients with preoperative insertion of an IVC filter
Patient No. Disease PE DVT Timing of insertion (days before surgery)
1 Benign ovarian tumor - + 1 day
2 Endometrial cancer + + 7 days
3 Ovarian cancer + + 2 days
4 Ovarian cancer - + 2 days
5 Ovarian cancer + + 1 day
6 Ovarian cancer + + 5 days
7 Ovarian cancer + + 2 days
8 Ovarian cancer + + 1 day
9 Ovarian cancer - + 6 days
10 Ovarian cancer + + 1 day
11 Ovarian cancer + + 1 day
12 Ovarian cancer + - 3 days
13 Ovarian cancer + + 15 days
DVT: deep venous thromboembolism; IVC: inferior vena cava; PE: pulmonary thromboembolism.
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immediately before surgery. An IVC filter was inserted
and radical surgery could be performed on the next day
without postponing treatment. Eleven of our 13 patients
(84.6%) with IVC filters had ovarian cancer. Adib et al.
also reported that the most common type of cancer in
patients with an IVC filter was ovarian cancer (61.5%)
[21]. The criteria for insertion of an IVC filter by Adib
et al. were (1) surgery was the primary treatment for
cancer, (2) surgery was part of definitive treatment, (3)
anticoagulation was contraindicated, or (4) after failed
anticoagulation [21]. Based on the above results, we per-
form VTE screening just before surgery in patients with
ovarian cancer, a tumor diameter ≥10 cm, or a history
of VTE. It is also important to consider use of an IVC
filter as required.
Characteristics of postoperative VTE in patients with
gynecologic diseases (Table 6)
Screening for postoperative VTE by interview and mea-
surement of D-dimer identified this condition in 14 out
of 1,232 patients (1.14%). These 14 patients consisted of
10 of the 368 patients undergoing cancer surgery
(2.72%) and four of the 864 patients having operations
for benign diseases (0.46%). Eight of these 14 patients
were given both IPC and the anticoagulant danaparoid
sodium. The operating time and mean blood loss of the
14 patients were 209.4 (58-375) minutes, and 1001.4
(10-3,230) ml respectively. Santoso et al. reported that
the incidence of postoperative DVT was 4.40% (30/684)
and 0.30% (2/720) in patients with malignant and benign
diseases, respectively [6], while Martino et al. reported
that the incidence was 4.1% (21/507) and 0.3% (1/332),
Figure 1 Profile of D-dimer values and preoperative CT findings in patient number 5. A: Day 1: first outpatient examination. Day 20:
admission, CT and IVC filter insertion. Day 21: operation. Day 33: IVC filter removal. B: Superior and inferior lobe branches of the right pulmonary
artery are not visualized (white circles). C: Posterior tibial vein and peroneal vein in the left leg show no enhancement (white circles).
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cancer surgery between our results and those of Santoso
et al. [6] or Martino et al. [13] may be related to differ-
ent postoperative prevention methods and differences of
patient characteristics such as ethnicity. The fact that
we perform screening for preoperative VTE just before
surgery might also contribute to a lower incidence of
postoperative VTE.
The 10 cancer patients with postoperative VTE con-
sisted of five (3.5%) with ovarian cancer, three (3%) with
uterine cervical cancer, and two (1.7%) with endometrial
cancer. Unlike preoperative VTE, ovarian cancer was
not significantly associated with postoperative VTE.
Two of the three patients with cervical cancer had ade-
nocarcinoma and one patient with endometrial cancer
had clear cell adenocarcinoma, suggesting the possibility
that uterine adenocarcinoma may be associated with a
h i g h e rr i s ko fp o s t o p e r a t i v eV T E .T w oo ft h ef i v eo v a r -
ian cancer patients also had clear cell adenocarcinoma.
Santoso et al. found no difference in the incidence of
postoperative DVT in relation to the type of cancer [6],
but Martino et al. reported that the incidence of post-
operative PE was 2.8% (2/72) for uterine cervical cancer,
1.2% (2/165) for endometrial cancer, and 6.8% (16/237)
for ovarian cancer [13]. Because of the strong possibility
that VTE is present preoperatively in ovarian cancer
patients, Martino et al. suggested that exclusion should
be performed by preoperative screening in patients with
suspected ovarian cancer.
T h em e a na g e ,m e a nB M I ,m e a nt u m o rd i a m e t e r ,
mean operating time, and mean blood loss of the 10
cancer patients with postoperative VTE was 60 (40-75)
years, 21.9 (16.4-27.8) kg/m
2, 9 (3-20) cm, 235.5 (58-
375) minutes, and 1,139 (10-3,230) ml. However, four
patients with benign disease included ovarian tumors (n
= 2), uterine myoma (n = 1), and intrauterine infection
(n = 1). The mean age, mean BMI, mean tumor dia-
meter, mean operating time, and mean amount of blood
loss in these four patients were 53.8 (44-64) years, 23.0
(19.6-27.2) kg/m
2, 12 (6-23) cm, 144.3 (75-176) minutes,
and 1,154 (30-2,100) ml, respectively. There were no sig-
nificant differences of these parameters between the 10
cancer patients and four patients with benign disease.
Five patients had DVT only, three had PE only, and PE
was combined with DVT in six patients.
Factors related to postoperative VTE
Univariate analysis using 21 variables showed that age
(≥50 or ≥55 years), a diagnosis of cancer, an operating
time ≥4 hours, blood loss (≥1,000 ml, 1,500 m, or 2,000
ml), and blood transfusion ≥2,000 ml were significantly
related to postoperative VTE (Table 6). When multivari-
ate analysis was performed using 13 variables, significant
associations were detected with cancer surgery tumors, a
history of allergic-immunologic disease, and blood trans-
fusion ≥2,000 ml, with risk ratios of 6.035, 4.816, and
6.206, respectively. Our previous multivariate analysis of
6,218 patients in whom only IPC was used for prevention
of VTE showed that cancer surgery, BMI ≥25 kg/m
2, and
blood transfusion were independent risk factors for post-
operative PE [4]. The fact that many of the 1,232 patients
in the present series received both IPC and anticoagula-
t i o nm a yb eo n eo ft h er e a s o n sw h yaB M I≥25 kg/m
2
was not identified as a significant risk factor. However,
Martino et al. only used IPC for prevention and identified
cancer surgery and an age ≥60 years as risk factors for
postoperative PE [13]. A recent report indicated that the
D-dimer level on postoperative day 3, use of recombinant
human erythropoietin, and blood group (non-O) were
independent risk factors for postoperative VTE in Japa-
nese patients with gynecologic cancer [22].
Conclusions
In patients with perioperative VTE, PE often leads to
fatal sequelae, so adequate screening for perioperative
VTE should be performed in the gynecologic field as is
done for orthopedic surgery. VTE should be prevented
by careful assessment of patients with the risk factors
identified in this study. Because the presence of VTE
before the start of treatment is a strong possibility in
ovarian cancer patients, preoperative screening is impor-
tant and consideration should be given to insertion of
an IVC filter when required.
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Table 6 Risk factors for postoperative VTE
Univariate analysis
Variable p value
Age ≥50 years <0.01
Age ≥55 years <0.01
Malignant disease <0.01
Operating time ≥4 hours <0.05
Blood loss ≥1,000 ml <0.05
Blood loss ≥1,500 ml <0.05
Blood loss ≥2,000 ml <0.01
Blood transfusion ≥2,000 ml <0.05
Multivariate analysis
Variable Risk ratio 95% CI p value
Lower Upper
Allergic-immunologic disease 4.816 1.010 22.956 <0.05
Malignant disease 6.035 1.881 19.359 <0.01
Blood transfusion ≥2,000 ml 6.206 1.248 30.862 <0.05
CI: confidence interval; VTE: venous thromboembolism.
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